| c-erbB2 oncogene expression is a valuable marker in the differential diagnosis and prognostic evaluation of patients with intraductal proliferative lesions. | None |
| Effects of the oncogenic V(664)E mutation on membrane insertion, structure, and sequence-dependent interactions of the Neu transmembrane domain in micelles and model membranes: an integrated biophysical and simulation study. | None |
| Expression screening of 17q12-21 amplicon reveals GRB7 as an ERBB2-dependent oncogene. | None |
| The HER2 proto-oncogene is located on chromosome 17q21 and encodes a 185-kDa transmembrane tyrosine kinase receptor, HER2 (also known as HER2/neu, ERBB2, p185) | None |
| Disruption of epithelial architecture caused by loss of PTEN or by oncogenic mutant p110alpha/PIK3CA but not by HER2 or mutant AKT1. | None |
| Suppression of oncoprotein Her-2 and DNA damage after treatment with Flavan-3- ol vitis labrusca extract. | None |
| Identification of relevant conformational epitopes on the HER2 oncoprotein by using Large Fragment Phage Display (LFPD). | None |
| The oncogene HER2/neu (ERBB2) requires the hypoxia-inducible factor HIF-1 for mammary tumor growth and anoikis resistance. | None |
| Amplification of Her-2/neu oncogene in GERD - Barrett s metaplasia - dysplasia - adenocarcinoma sequence. | None |
| the acquired substrate preference for GAB1 is critical for the ERBB2 mutant-induced oncogenesis. | None |
| HER-2/neu mediates oncogenic transformation via altered CREB expression and function. | None |
| c-erbB-2 oncoprotein expression in primary human tumors. | None |
| Strong dimerization of wild-type ErbB2/Neu transmembrane domain and the oncogenic Val664Glu mutant in mammalian plasma membranes. | None |
| Ligand-independent tyrosine phosphorylation of EGF receptor and the erbB-2/neu proto-oncogene product is induced by hyperosmotic shock. | None |
| Regulation of HER2 oncogene transcription by a multifunctional coactivator/corepressor complex. | None |
| The overexpression of a single oncogene (ERBB2/HER2) alters the proteomic landscape of extracellular vesicles. | None |
| Distinct regulatory effect of the p34SEI-1 oncoprotein on cancer metastasis in HER2/neu-positive and -negative cells. | None |
| The HER2 oncogene is a bi-functional locus. | None |
| The HER2-encoded miR-4728-3p regulates ESR1 through a non-canonical internal seed interaction. | None |
| Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin. | None |